KRAS and adenocarcinoma: Li et al. [81] performed whole-genome CRISPR screening on SHP2-inhibited and -uninhibited KRAS-mutant gastroesophageal adenocarcinoma (GEA, a type of cancer that originates from the glandular cells in the stomach or lower part of the esophagus, also known as adenocarcinoma of the gastroesophageal junction) cells and identified the MAPK pathway and the upstream RTK pathway, the inhibition of which enhances the efficacy of SHP2 inhibition in KRAS-mutant GEA.